27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Bank of America Merrill Lynch analyst Sumant Kulkarni added Allergan plc (NYSE: AGN) shares to the firm's esteemed US-1 list Tuesday morning. The analyst reiterated a Buy rating and boosted his price objective on the stock from $287 to $294.
"AGN shares are down ~30% this year, driven in part by the breakup of the Pfizer-AGN merger, which we believe creates a particularly attractive opportunity to own a relatively high-quality Pharma stock with limited “Brexit” exposure," Kulkarni said.
Kulkarni highlighted three points as to why Allergan has positioned itself appropriately within the industry:
- "A product mix that includes lucrative/sticky franchises (Botox, implants, etc.),
- ~15 potential launches in 2016, and
- A robust pipeline (70+ programs)."
On the heels of the Generics unit sale, $10 billion buyback plan and repayment of $8 billion in debt, Kulkarni said Allergan will have about $18 billion in "dry powder" left.
As Allergan shares closed Tuesday's session up nearly 5 percent at $227.72, Kulkarni's new price objective represented potential upside of about 29 percent.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!